Leang R, Khu NH, Mukaka M, Debackere M, Tripura R, et al.
2016-10-27 • BMC Medicine
2016-10-27 • BMC Medicine
BACKGROUND In 2012, the World Health Organization recommended the addition of single low-dose primaquine (SLDPQ, 0.25 mg base/kg body weight) to artemisinin combination therapies to ...
Taylor WRJ, Hoglund RM, Peerawaranun P, Nguyen TN, Hien TT, et al.
2021-09-09 • Malaria Journal
2021-09-09 • Malaria Journal
BACKGROUND In many endemic areas, Plasmodium vivax malaria is predominantly a disease of young adults and children. International recommendations for radical cure recommend fixed tar...
Grist EP, Fleqq JA, Humphreys G, Mas IS, Anderson TJC, et al.
2016-10-24 • International Journal of Health Geographics
2016-10-24 • International Journal of Health Geographics
BACKGROUND Artemisinin-resistant Plasmodium falciparum malaria parasites are now present across much of mainland Southeast Asia, where ongoing surveys are measuring and mapping their...
Taylor WRJ, Naw HK, Maitland K, Williams TN, Kapulu M, et al.
2018-01-18 • BMC Medicine
2018-01-18 • BMC Medicine
In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), wi...
Hossain MS, Commons RJ, Douglas NM, Thriemer KL, Alemayehu BH, et al.
2020-11-19 • PLOS Medicine
2020-11-19 • PLOS Medicine
Background: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using a...
